Bijal J Modi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bijal J Modi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Arno J Mundt
University of Illinois Medical Center, 840 South Wood Street, Chicago, IL 60612, USA
1 shared publicationBrian Knab
University of Illinois Medical Center, 840 South Wood Street, Chicago, IL 60612, USA
1 shared publicationJoel Epstein
University of Illinois Medical Center, 840 South Wood Street, Chicago, IL 60612, USA
1 shared publicationKristen B Pytynia
University of Illinois Medical Center, 840 South Wood Street, Chicago, IL 60612, USA
1 shared publicationLawrence E Feldman
University of Illinois Medical Center, 840 South Wood Street, Chicago, IL 60612, USA
1 shared publicationMike Yao
University of Illinois Medical Center, 840 South Wood Street, Chicago, IL 60612, USA
1 shared publication
Latest Publications
- 15 June 2005
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 6 (7) , 1143-1155
Review of current treatment practices for carcinoma of the head and neck
The past two decades have witnessed a paradigm shift in the treatment of squamous cell carcinoma of the head and neck. Innovation in chemotherapy, radiotherapy and surgery has led to the assimilation of these modalities into our treatment algorithms. This modern multipart treatment plan has led to improved survival; however, this has come at the cost of increased toxicity. New and future therapies will be more tumour specific and, ideally, less toxic. Current research centres on these tumour-specific therapies with the anticipation of improved survival with decreased toxicity. This article will review the standard of care, recent advances and unfulfilled needs in the treatment of squamous cell carcinoma of the head and neck.
- 15 June 2005
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 6 (7) , 1143-1155
Review of current treatment practices for carcinoma of the head and neck
The past two decades have witnessed a paradigm shift in the treatment of squamous cell carcinoma of the head and neck. Innovation in chemotherapy, radiotherapy and surgery has led to the assimilation of these modalities into our treatment algorithms. This modern multipart treatment plan has led to improved survival; however, this has come at the cost of increased toxicity. New and future therapies will be more tumour specific and, ideally, less toxic. Current research centres on these tumour-specific therapies with the anticipation of improved survival with decreased toxicity. This article will review the standard of care, recent advances and unfulfilled needs in the treatment of squamous cell carcinoma of the head and neck.